ArticleTargeted oncology2023

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.

Kenji Morimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.